MedTrace Logo

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

NCT05172037 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2022-03-03

No results posted yet for this study

Summary

An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19

Conditions

  • Covid19

Interventions

BIOLOGICAL

Novaferon

a novel recombinant antiviral protein drug

BIOLOGICAL

Placebo

Saline

Sponsors & Collaborators

  • Tokyo Shinagawa Hospital

    collaborator OTHER

  • Genova Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2022-03-31
Completion
2022-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172037 on ClinicalTrials.gov